Back to Trades
Schneiderman Daniel H
Chief Financial OfficerCIK 0001565536
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 3
- Buy transactions
- 0
- Sell transactions
- 0
- Companies
- 1
- Active
- 2025–2026
Across 3 filings between 2025–2026, Schneiderman Daniel H, Chief Financial Officer, has disclosed $1.2M in transactions — all concentrated in Pasithea Therapeutics Corp. (KTTA). Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
3 loaded
| May 5 | KTTA Pasithea Therapeutics Corp. | Schneiderman Daniel H | Chief Financial Officer | Award | $949.8K |
| Dec 1 | KTTA Pasithea Therapeutics Corp. | Schneiderman Daniel H | Chief Financial Officer | Grant | $20.0K |
| Oct 27 | KTTA Pasithea Therapeutics Corp. | Schneiderman Daniel H | Chief Financial Officer | Award | $226.8K |
3 filings